Rabindranath K, Adams J, Macleod A M, Muirhead N
Churchill Hospital, Renal Unit, Oxford, UK, OX3 7LJ.
Cochrane Database Syst Rev. 2007 Jul 18(3):CD003773. doi: 10.1002/14651858.CD003773.pub3.
Renal replacement therapy (RRT) for acute renal failure (ARF) can be applied intermittently (IRRT) or continuously (CRRT). It has been suggested that CRRT has several advantages over IRRT including better haemodynamic stability, lower mortality and higher renal recovery rates.
To compare CRRT with IRRT to establish if any of these techniques is superior to each other in patients with ARF.
We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL). Authors of included studies were contacted, reference lists of identified studies and relevant narrative reviews were screened. Search date: October 2006.
RCTs comparing CRRT with IRRT in adult patients with ARF and reporting prespecified outcomes of interest were included. Studies assessing CAPD were excluded.
Two authors assessed trial quality and extracted data. Statistical analyses were performed using the random effects model and the results expressed as relative risk (RR) for dichotomous outcomes or mean difference (WMD) for continuous data with 95% confidence intervals (CI).
We identified 15 studies (1550 patients). CRRT did not differ from IRRT with respect to in-hospital mortality (RR 1.01, 95% CI 0.92 to 1.12), ICU mortality (RR 1.06, 95% CI 0.90 to 1.26), number of surviving patients not requiring RRT (RR 0.99, 95% CI 0.92 to 1.07), haemodynamic instability (RR 0.48, 95% CI 0.10 to 2.28) or hypotension (RR 0.92, 95% CI 0.72 to 1.16) and need for escalation of pressor therapy (RR 0.53, 95% CI 0.26 to 1.08). Patients on CRRT were likely to have significantly higher mean arterial pressure (MAP) (WMD 5.35, 95% CI 1.41 to 9.29) and higher risk of clotting dialysis filters (RR, 95% CI 8.50 CI 1.14 to 63.33).
AUTHORS' CONCLUSIONS: In patients who are haemodynamically stable, the RRT modality does not appear to influence important patient outcomes, and therefore the preference for CRRT over IRRT in such patients does not appear justified in the light of available evidence. CRRT was shown to achieve better haemodynamic parameters such as MAP. Future research should focus on factors such as the dose of dialysis and evaluation of newer promising hybrid technologies such as SLED. Triallists should follow the recommendations regarding clinical endpoints assessment in RCTs in ARF made by the Working Group of the Acute Dialysis Quality Initiative Working Group.
急性肾衰竭(ARF)的肾脏替代治疗(RRT)可采用间歇性(IRRT)或连续性(CRRT)方式。有人提出,CRRT相对于IRRT具有若干优势,包括更好的血流动力学稳定性、更低的死亡率和更高的肾脏恢复率。
比较CRRT和IRRT,以确定这两种技术在ARF患者中是否有一方优于另一方。
我们检索了MEDLINE、EMBASE、Cochrane对照试验中心注册库(CENTRAL)。我们联系了纳入研究的作者,筛选了已识别研究的参考文献列表和相关的叙述性综述。检索日期:2006年10月。
纳入比较CRRT和IRRT治疗成年ARF患者并报告预先指定的感兴趣结局的随机对照试验(RCT)。评估持续性非卧床腹膜透析(CAPD)的研究被排除。
两位作者评估试验质量并提取数据。采用随机效应模型进行统计分析,结果以二分类结局的相对危险度(RR)或连续性数据的平均差(WMD)表示,并给出95%置信区间(CI)。
我们识别出15项研究(1550例患者)。在住院死亡率(RR 1.01,95%CI 0.92至1.12)、重症监护病房(ICU)死亡率(RR 1.06,95%CI 0.90至1.26)、无需RRT的存活患者数量(RR 0.99,95%CI 0.92至1.07)、血流动力学不稳定(RR 0.48,95%CI 0.10至2.28)或低血压(RR 0.92,95%CI 0.72至1.16)以及升压治疗升级需求(RR 0.53,95%CI 0.26至1.08)方面,CRRT与IRRT没有差异。接受CRRT的患者平均动脉压(MAP)可能显著更高(WMD 5.35,95%CI 1.41至9.29),且透析滤器凝血风险更高(RR,95%CI 8.50 CI 1.14至63.33)。
在血流动力学稳定的患者中,RRT方式似乎不影响重要的患者结局,因此,根据现有证据,在此类患者中优先选择CRRT而非IRRT似乎没有依据。CRRT被证明能实现更好的血流动力学参数,如MAP。未来的研究应聚焦于透析剂量等因素以及对诸如缓慢低效血液透析(SLED)等更新的有前景的混合技术的评估。试验者应遵循急性透析质量改进工作组为ARF的RCT中临床终点评估所提出的建议。